CNS-accessible Inhibitor of Glucosylceramide Synthase for Substrate Reduction Therapy of Neuronopathic Gaucher Disease

[1]  B. Wang,et al.  Efficacy of Enzyme and Substrate Reduction Therapy with a Novel Antagonist of Glucosylceramide Synthase for Fabry Disease , 2015, Molecular medicine.

[2]  R. Schiffmann,et al.  Identification of a Biomarker in Cerebrospinal Fluid for Neuronopathic Forms of Gaucher Disease , 2015, PloS one.

[3]  A. Futerman,et al.  Emerging therapeutic targets for Gaucher disease , 2015, Expert opinion on therapeutic targets.

[4]  G. Lopez,et al.  The clinical management of Type 2 Gaucher disease. , 2015, Molecular genetics and metabolism.

[5]  Ying Sun,et al.  CNS, lung, and lymph node involvement in Gaucher disease type 3 after 11 years of therapy: clinical, histopathologic, and biochemical findings. , 2015, Molecular genetics and metabolism.

[6]  A. Futerman,et al.  From sheep to mice to cells: tools for the study of the sphingolipidoses. , 2014, Biochimica et biophysica acta.

[7]  C. Hollak,et al.  A systematic review on effectiveness and safety of eliglustat for type 1 Gaucher disease , 2014 .

[8]  A. Merrill,et al.  Neuronal accumulation of glucosylceramide in a mouse model of neuronopathic Gaucher disease leads to neurodegeneration. , 2014, Human molecular genetics.

[9]  F. Platt,et al.  RIPK3 as a potential therapeutic target for Gaucher's disease , 2014, Nature Medicine.

[10]  M. Delpino,et al.  Uncoupling of osteoblast-osteoclast regulation in a chemical murine model of Gaucher disease. , 2013, Gene.

[11]  M. Górecki,et al.  Glucosylceramide Mimics: Highly Potent GCase Inhibitors and Selective Pharmacological Chaperones for Mutations Associated with Types 1 and 2 Gaucher Disease , 2013, ChemMedChem.

[12]  F. Platt,et al.  β-Glucosidase 2 (GBA2) Activity and Imino Sugar Pharmacology* , 2013, The Journal of Biological Chemistry.

[13]  M. Machaczka.  Allogeneic Hematopoietic Stem Cell Transplantation for Treatment of Gaucher Disease , 2013, Pediatric hematology and oncology.

[14]  D. Dickson,et al.  Atp13a2-deficient mice exhibit neuronal ceroid lipofuscinosis, limited α-synuclein accumulation and age-dependent sensorimotor deficits. , 2013, Human molecular genetics.

[15]  Ying Sun,et al.  Substrate Compositional Variation with Tissue/Region and Gba1 Mutations in Mouse Models–Implications for Gaucher Disease , 2013, PloS one.

[16]  A. Barrett,et al.  Gauchers Disease—A Reappraisal of Hematopoietic Stem Cell Transplantation , 2013, Pediatric hematology and oncology.

[17]  C. Pignata,et al.  New strategies for the treatment of lysosomal storage diseases (review). , 2013, International journal of molecular medicine.

[18]  R. Scheule,et al.  Systemic Delivery of a Glucosylceramide Synthase Inhibitor Reduces CNS Substrates and Increases Lifespan in a Mouse Model of Type 2 Gaucher Disease , 2012, PloS one.

[19]  I. Biton,et al.  Contribution of brain inflammation to neuronal cell death in neuronopathic forms of Gaucher's disease. , 2012, Brain : a journal of neurology.

[20]  A. Futerman,et al.  Animal models for Gaucher disease research , 2011, Disease Models & Mechanisms.

[21]  R. Schiffmann,et al.  The Saccadic and Neurological Deficits in Type 3 Gaucher Disease , 2011, PloS one.

[22]  A. Tylki-Szymańska,et al.  Four-year follow-up of chronic neuronopathic Gaucher disease in Europeans using a modified severity scoring tool , 2011, Journal of Inherited Metabolic Disease.

[23]  J. M. Benito,et al.  Pharmacological chaperone therapy for Gaucher disease: a patent review , 2011, Expert opinion on therapeutic patents.

[24]  Ying Sun,et al.  Isofagomine In Vivo Effects in a Neuronopathic Gaucher Disease Mouse , 2011, PloS one.

[25]  R. Sidman,et al.  Relationship between neuropathology and disease progression in the SOD1G93A ALS mouse , 2011, Experimental Neurology.

[26]  D. Rosenthal,et al.  Improvement in hematological, visceral, and skeletal manifestations of Gaucher disease type 1 with oral eliglustat tartrate (Genz-112638) treatment: 2-year results of a phase 2 study. , 2010, Blood.

[27]  R. Scheule,et al.  Intracerebroventricular delivery of glucocerebrosidase reduces substrates and increases lifespan in a mouse model of neuronopathic Gaucher disease , 2010, Experimental Neurology.

[28]  P. Bonate,et al.  A phase 2 study of eliglustat tartrate (Genz-112638), an oral substrate reduction therapy for Gaucher disease type 1. , 2010, Blood.

[29]  J. Matsuda,et al.  A mutation in the saposin C domain of the sphingolipid activator protein (Prosaposin) gene causes neurodegenerative disease in mice , 2010, Journal of neuroscience research.

[30]  A. Futerman,et al.  The Role of the Ceramide Acyl Chain Length in Neurodegeneration: Involvement of Ceramide Synthases , 2010, NeuroMolecular Medicine.

[31]  M. Patterson,et al.  Miglustat in adult and juvenile patients with Niemann-Pick disease type C: long-term data from a clinical trial. , 2010, Molecular genetics and metabolism.

[32]  R. Scheule,et al.  Improved management of lysosomal glucosylceramide levels in a mouse model of type 1 Gaucher disease using enzyme and substrate reduction therapy , 2010, Journal of Inherited Metabolic Disease.

[33]  Ying Sun,et al.  Neuronopathic Gaucher disease in the mouse: viable combined selective saposin C deficiency and mutant glucocerebrosidase (V394L) mice with glucosylsphingosine and glucosylceramide accumulation and progressive neurological deficits , 2010, Human molecular genetics.

[34]  J. Charrow,et al.  Dose-response relationships for enzyme replacement therapy with imiglucerase/alglucerase in patients with Gaucher disease type 1 , 2009, Genetics in Medicine.

[35]  R. Schiffmann,et al.  Randomized, controlled trial of miglustat in Gaucher's disease type 3 , 2008, Annals of neurology.

[36]  D. Witte,et al.  Dependence of reversibility and progression of mouse neuronopathic Gaucher disease on acid beta-glucosidase residual activity levels. , 2008, Molecular genetics and metabolism.

[37]  D. Elstein,et al.  No justification for very high-dose enzyme therapy for patients with type III Gaucher disease , 2007, Journal of Inherited Metabolic Disease.

[38]  A. Tylki-Szymańska,et al.  Outcome of type III Gaucher disease on enzyme replacement therapy: Review of 55 cases , 2007, Journal of Inherited Metabolic Disease.

[39]  J. Shayman,et al.  A specific and potent inhibitor of glucosylceramide synthase for substrate inhibition therapy of Gaucher disease. , 2007, Molecular genetics and metabolism.

[40]  G J Murray,et al.  Image-guided, direct convective delivery of glucocerebrosidase for neuronopathic Gaucher disease , 2007, Neurology.

[41]  David S. Wishart,et al.  The Online Metabolic and Molecular Bases of Inherited Disease; Chapter 3.1: Metabolism and Metabolic Disease Resources on the Web, Page 1 , 2007 .

[42]  J. Sussman,et al.  X-ray structure of human acid-beta-glucosidase covalently bound to conduritol-B-epoxide. Implications for Gaucher disease. , 2005, The Journal of biological chemistry.

[43]  G. Andria,et al.  The role of the iminosugar N-butyldeoxynojirimycin (miglustat) in the management of type I (non-neuronopathic) Gaucher disease: A position statement , 2003, Journal of Inherited Metabolic Disease.

[44]  B. Bembi,et al.  Glycolipid Analysis of Different Tissues and Cerebrospinal Fluid in Type II Gaucher Disease , 2002, Journal of Inherited Metabolic Disease.

[45]  C. Scriver,et al.  The Metabolic and Molecular Bases of Inherited Disease, 8th Edition 2001 , 2001, Journal of Inherited Metabolic Disease.

[46]  M. Herkenham,et al.  Toxicity of glucosylsphingosine (glucopsychosine) to cultured neuronal cells: a model system for assessing neuronal damage in Gaucher disease type 2 and 3 , 2003, Neurobiology of Disease.

[47]  E. Ginns,et al.  Glucosylsphingosine accumulation in tissues from patients with Gaucher disease: correlation with phenotype and genotype. , 2002, Molecular genetics and metabolism.

[48]  J. Marshall,et al.  Demonstration of feasibility of in vivo gene therapy for Gaucher disease using a chemically induced mouse model. , 2002, Molecular therapy : the journal of the American Society of Gene Therapy.

[49]  P. Kaplan,et al.  Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry. , 2002, The American journal of medicine.

[50]  R. Albin,et al.  Neurological abnormalities in a knock-in mouse model of Huntington's disease. , 2001, Human molecular genetics.

[51]  E. Ginns,et al.  Glucosylsphingosine Accumulation in Mice and Patients with Type 2 Gaucher Disease Begins Early in Gestation , 2000, Pediatric Research.

[52]  J. Aerts.  The European Working Group on Gaucher Disease , 1996 .

[53]  O. Ringdén,et al.  Ten years' experience of bone marrow transplantation for Gaucher disease. , 1995, Transplantation.

[54]  R. Van Tiggelen,et al.  Gaucher disease , 2019, Haematology.

[55]  L. Svennerholm,et al.  Accumulation of Glucosylceramide and Glucosylsphingosine (Psychosine) in Cerebrum and Cerebellum in Infantile and Juvenile Gaucher Disease , 1982, Journal of neurochemistry.

[56]  N. Radin,et al.  Destruction and resynthesis of mouse beta-glucosidases. , 1979, Biochimica et biophysica acta.

[57]  J. Kanfer,et al.  THE GAUCHER MOUSE: DIFFERENTIAL ACTION OF CONDURITOL B EPOXIDE AND REVERSIBILITY OF ITS EFFECTS , 1978, Journal of neurochemistry.

[58]  J. Kanfer,et al.  The Gaucher mouse. , 1975, Biochemical and biophysical research communications.